Please login to the form below

Not currently logged in
Email:
Password:

Takeda UK & Ireland appoints market access director

Peter Wheatley Price brings experience from GSK, Janssen and Boehringer Ingelheim

Takeda UK & Ireland Peter Wheatley PriceTakeda UK & Ireland has appointed Peter Wheatley Price as market access director, succeeding Ross Selby who moves to head the firm's new US-based global pricing, market access and health economics oncology division.

Wheatley Price joins Takeda from GlaxoSmithKline, where he served as global market access and pricing director from 2014 to January this year, during which time he oversaw the launch of the company's first respiratory biologic for severe asthma.

Prior to this, Wheatley Price was associate director of health economics market access and reimbursement for oncology across Europe, the Middle East and Africa at Janssen, having joined as interim head of outcomes research in 2010.

He also brings experience form Boehringer Ingelheim, where he was director of its UK Change Project, head of UK market access for prescription medicines, and held a series of marketing management positions.

Adam Zaeske, managing director of Takeda UK, said: “Owing to our ambitions to continue to deliver improved outcomes both for patients and our customers, I am delighted that we have been able to attract such a strong talent as Peter to take on such an important role in our organisation.

“It is clear to me that he shares our vision for Takeda and has both the experience and passion to help us to grow the business.”

27th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics